Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AURA NASDAQ:CADL NASDAQ:MRSN NASDAQ:PROK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAURAAura Biosciences$8.40+2.4%$6.66$4.34▼$9.53$539.28M0.37679,491 shs1.05 million shsCADLCandel Therapeutics$8.35+7.2%$5.47$4.35▼$8.36$611.80M-0.591.99 million shs2.53 million shsMRSNMersana Therapeutics$29.08+0.1%$28.83$5.21▼$30.39$145.37M0.44112,909 shs712,400 shsPROKProKidney$1.86-1.1%$2.02$0.54▼$7.13$561.56M1.7959,263 shs719,050 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAURAAura Biosciences+2.44%+19.83%+23.89%+50.00%+69.97%CADLCandel Therapeutics+7.19%+29.06%+73.96%+43.22%+84.94%MRSNMersana Therapeutics0.00%0.00%0.00%0.00%+260.12%PROKProKidney-1.06%-3.63%-2.11%-0.53%+190.49%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAURAAura Biosciences$8.40+2.4%$6.66$4.34▼$9.53$539.28M0.37679,491 shs1.05 million shsCADLCandel Therapeutics$8.35+7.2%$5.47$4.35▼$8.36$611.80M-0.591.99 million shs2.53 million shsMRSNMersana Therapeutics$29.08+0.1%$28.83$5.21▼$30.39$145.37M0.44112,909 shs712,400 shsPROKProKidney$1.86-1.1%$2.02$0.54▼$7.13$561.56M1.7959,263 shs719,050 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAURAAura Biosciences+2.44%+19.83%+23.89%+50.00%+69.97%CADLCandel Therapeutics+7.19%+29.06%+73.96%+43.22%+84.94%MRSNMersana Therapeutics0.00%0.00%0.00%0.00%+260.12%PROKProKidney-1.06%-3.63%-2.11%-0.53%+190.49%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAURAAura Biosciences 2.40Hold$21.50155.95% UpsideCADLCandel Therapeutics 2.44Hold$18.00115.57% UpsideMRSNMersana Therapeutics 1.88Reduce$38.1931.32% UpsidePROKProKidney 2.50Moderate Buy$7.40297.85% UpsideCurrent Analyst Ratings BreakdownLatest MRSN, CADL, AURA, and PROK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/29/2026AURAAura Biosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$22.00 ➝ $24.004/21/2026PROKProKidney Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026CADLCandel Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026CADLCandel Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight4/7/2026CADLCandel Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell3/30/2026AURAAura Biosciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$22.003/27/2026AURAAura Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/18/2026PROKProKidney Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy3/13/2026CADLCandel Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$24.00 ➝ $22.003/13/2026CADLCandel Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.003/9/2026CADLCandel Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold(Data available from 5/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAURAAura BiosciencesN/AN/AN/AN/A$2.16 per shareN/ACADLCandel TherapeuticsN/AN/AN/AN/A$0.95 per shareN/AMRSNMersana Therapeutics$33.18M4.38N/AN/A($1.92) per share-15.15PROKProKidney$893K628.85N/AN/A($3.36) per share-0.55Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAURAAura Biosciences-$106.19M-$1.79N/AN/AN/AN/A-71.25%-59.06%5/14/2026 (Estimated)CADLCandel Therapeutics-$38.18M-$0.71N/AN/AN/AN/A-51.44%-36.31%5/12/2026 (Estimated)MRSNMersana Therapeutics-$69.19M-$13.88N/AN/AN/A-211.21%N/A-65.42%N/APROKProKidney-$68.99M-$0.52N/AN/AN/A-7,725.20%N/A-18.83%5/11/2026 (Estimated)Latest MRSN, CADL, AURA, and PROK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026AURAAura Biosciences-$0.40N/AN/AN/AN/AN/A5/12/2026Q1 2026CADLCandel Therapeutics-$0.2958N/AN/AN/AN/AN/A5/11/2026Q1 2026PROKProKidney-$0.13N/AN/AN/A$0.10 millionN/A3/30/2026Q4 2025AURAAura Biosciences-$0.43-$0.37+$0.06-$0.37N/AN/A3/18/2026Q4 2025PROKProKidney-$0.16-$0.14+$0.02-$0.13$0.00 million$0.23 million3/12/2026Q4 2025CADLCandel Therapeutics-$0.24-$0.54-$0.30-$0.54N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAURAAura BiosciencesN/AN/AN/AN/AN/ACADLCandel TherapeuticsN/AN/AN/AN/AN/AMRSNMersana TherapeuticsN/AN/AN/AN/AN/APROKProKidneyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAURAAura BiosciencesN/A8.158.15CADLCandel Therapeutics0.9113.4913.49MRSNMersana TherapeuticsN/A1.391.39PROKProKidneyN/A9.139.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAURAAura Biosciences96.75%CADLCandel Therapeutics13.93%MRSNMersana Therapeutics93.92%PROKProKidney51.59%Insider OwnershipCompanyInsider OwnershipAURAAura Biosciences6.30%CADLCandel Therapeutics16.60%MRSNMersana Therapeutics13.00%PROKProKidney39.83%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAURAAura Biosciences5064.20 million60.16 millionNot OptionableCADLCandel Therapeutics6073.27 million61.11 millionOptionableMRSNMersana Therapeutics1505.00 million4.35 millionOptionablePROKProKidney3301.92 million181.66 millionOptionableMRSN, CADL, AURA, and PROK HeadlinesRecent News About These CompaniesSigyn Therapeutics (OTCMKTS:SIGY) vs. ProKidney (NASDAQ:PROK) Head to Head Contrast1 minutes ago | americanbankingnews.comProKidney (PROK) to Release Quarterly Earnings on MondayMay 4, 2026 | marketbeat.comProKidney (PROK) Appoints Greg Madison as CCO to Lead Commercial Strategy for RilparencelMay 2, 2026 | finance.yahoo.comProKidney (NASDAQ:PROK) Upgraded to Sell at Wall Street ZenApril 18, 2026 | marketbeat.comProKidney (NASDAQ:PROK) Stock Price Up 9% - Should You Buy?April 17, 2026 | marketbeat.comProKidney Corp. (NASDAQ:PROK) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesApril 16, 2026 | marketbeat.comProKidney Corp. Class AApril 14, 2026 | edition.cnn.comProKidney (NASDAQ:PROK) Sees Strong Trading Volume - Time to Buy?April 13, 2026 | marketbeat.comApril 2026 Penny Stock HighlightsApril 3, 2026 | finance.yahoo.comWhat Makes ProKidney Corp. (PROK) So AttractiveMarch 31, 2026 | insidermonkey.comWhat makes ProKidney Corp. (PROK) so attractiveMarch 31, 2026 | msn.com5 Best Penny Stocks That Could Triple Your MoneyMarch 30, 2026 | insidermonkey.comProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial OfficerMarch 25, 2026 | globenewswire.comProKidney Corp. (NASDAQ:PROK) Given Consensus Recommendation of “Moderate Buy†by BrokeragesMarch 22, 2026 | defenseworld.netDProKidney narrows loss to $150M as it eyes crucial kidney treatment trial resultsMarch 20, 2026 | bizjournals.comTrade Policy Risks: How Evolving U.S. Tariffs and Export Rules Threaten ProKidney Corp.’s Supply Chain and Financial StabilityMarch 20, 2026 | tipranks.comProKidney Reports Full Year 2025 Financial Results and Business HighlightsMarch 19, 2026 | finance.yahoo.com3 Promising Penny Stocks With At Least $600M Market CapFebruary 12, 2026 | finance.yahoo.comProKidney Stock: Differentiated CKD Approach Positions Rilparencel FavorablyJanuary 31, 2026 | seekingalpha.comFood & Drug Experts Say New Kidney Cell Therapy Could Transform Chronic Disease TreatmentJanuary 15, 2026 | msn.comProKidney Corp. (PROK) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptJanuary 14, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWith Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?By Sam Quirke | April 12, 2026The Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 2026Does Cheesecake Factory Stock Have Any Upside Left on the Menu?By Jennifer Ryan Woods | April 27, 2026Chipotle Stock Just Hit Bottom—Is a Breakout Next?By Thomas Hughes | April 30, 2026Toast Finally Cracks Profit—But a Bigger Risk LoomsBy Peter Frank | April 23, 2026MRSN, CADL, AURA, and PROK Company DescriptionsAura Biosciences NASDAQ:AURA$8.40 +0.20 (+2.44%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$8.39 -0.01 (-0.12%) As of 05/8/2026 05:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.Candel Therapeutics NASDAQ:CADL$8.35 +0.56 (+7.19%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$8.33 -0.02 (-0.29%) As of 05/8/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.Mersana Therapeutics NASDAQ:MRSNMersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.ProKidney NASDAQ:PROK$1.86 -0.02 (-1.06%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$1.90 +0.03 (+1.88%) As of 05/8/2026 05:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/04 - 05/08 SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
